Hypothalamic peptide (GnRH)
Gonadorelin
Gonadorelin after one dose: 50% at ~4 min, 25% at 8 min, 12.5% at 12 min.
Drawn from the half-life in the app's model, ~4 min. The model's figures
- Compound
- Gonadorelin
- Symbol
- GON
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 22
- Checked
- Last reviewed . Sources are listed below.
Overview
Gonadorelin is the gonadotropin-releasing hormone (GnRH) produced by the hypothalamus, a decapeptide of ten amino acids.5,6
A search of DailyMed on 16 November 2026 for "gonadorelin" returned five labels, Factrel, Gonabreed, Cystorelin, Fertagyl and OvaCyst, each for dairy or beef cattle.5,6 The Cystorelin label states "Not for use in humans".6
The World Anti-Doping Agency's 2026 Prohibited List names GnRH and gonadorelin in S2.2.1, testosterone-stimulating peptides in males, in a class prohibited at all times.4
The human studies below used pulsatile GnRH or gonadorelin, by portable pump or by subcutaneous or intravenous pulses where the entries state the route, in men with hypogonadotropic hypogonadism, in women with hypothalamic amenorrhea, and in diagnostic stimulation testing.8,9,10
How it works
Wang and colleagues (Endocrine Connections, 2025) write that "The frequency of GnRH secretion in healthy males is 7–17 times per day, with a short half-life of only 2–4 min".11 A 2024 review of GnRH antagonists in Pharmaceuticals states that "Non-pulsatile or continuous GnRH production could result in the pituitary response's desensitization and reduced gonadotropin output".12 Hoffman and Crowley (New England Journal of Medicine, 1982) wrote that "Puberty is heralded by the appearance of episodic gonadotropin secretion".13
Handelsman and colleagues (Journal of Clinical Endocrinology and Metabolism, 1984) wrote that "deficient responses were observed with the sc in contrast to the iv route of hormone delivery" in pulsatile GnRH treatment, and compared the two routes in 14 hypogonadotropic patients (11 women and 3 men).14 In patients on programmed portable minipumps, "plasma IR-GnRH profiles were highly damped after sc administration, but retained an intermittent pulse wave form with the iv route".14
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 min
- Bioavailability
- 80%
- Typical dose
- 50–100 mcg/day
- Route
- SubQ
- Time to peak
- ~5 min
The app lists a half-life of about 4 minutes (0.07 hours), a bioavailability of 80% by subcutaneous injection and a time to peak of about 5 minutes (0.08 hours).
| Parameter | App figure | What sources report |
|---|---|---|
| Half-life | ~4 min | Source figures: 2.4 ± 0.4 min after intravenous injection in 6 volunteers, calculated over minutes 3 to 10 (Fauconnier and colleagues, 1978);1 5.5 to 8 min for the first component after infusion in normal subjects (Pimstone and colleagues, 1977);2 5.6 ± 0.4 min for the initial half-time in normal women (Chikamori and colleagues, 1981);15 7.8 ± 1.1 min in 8 normal subjects (Barron and colleagues, 1982).3 Wang and colleagues (2025) state 2–4 min.11 |
| Bioavailability (subcutaneous) | 80% | Source figure: during a 6-hour continuous infusion (3.17 µg/h; n = 11 of the 14 hypogonadotropic patients), plateau levels of immunoreactive GnRH between 2 and 6 h were 34% lower with subcutaneous delivery than intravenous (67.5 vs 102.4 pg/ml), which the authors read as "irreversible losses of about one third of GnRH injected sc"; the paper's summary gives no percentage bioavailability figure.14 |
| Time to peak | ~5 min | After a 5 µg bolus (n = 6), plasma GnRH peaked earlier and higher after intravenous than subcutaneous injection (400 vs 93.5 pg/ml) and returned to baseline in under 60 min versus over 120 min; levels were lower after subcutaneous injection between 1 and 5 min and higher between 30 and 90 min; the paper's summary gives no time to peak in minutes.14 |
| Clearance in kidney disease | Not in the app | Metabolic clearance in normal subjects was 1640 ± 59.7 ml/min and in chronic renal failure 631 ± 62 ml/min, (Pimstone and colleagues, 1977).2 |
The chart below uses the app's half-life of 0.07 hours and time to peak of 0.08 hours with doses every 90 minutes, the interval used in the pump trial of Zhang and colleagues (2019), as an illustration and not measured levels; Handelsman and colleagues found damped subcutaneous profiles on minipumps.8,14
Level over 1 days
Level, as a share of the peak after one 10 mcg dose
As studied: every 90 minutes (pump)8.
An illustration from a pharmacokinetic model using a half-life of 0.07 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Hoffman and Crowley, New England Journal of Medicine, 198213 | Six men treated, compared with their own values before therapy | 6 men with idiopathic hypogonadotropic hypogonadism | Long-term pulsatile subcutaneous GnRH by portable pump; dose not stated in the PubMed entry | Testosterone (mean ± SE) 77 ± 13 ng per deciliter before therapy and 520 ± 182 after one month (P less than 0.001); gonadotropins reached normal adult ranges within one week and supraphysiologic levels by 14 days; testis size rose in 4 men and spermatogenesis was achieved in 3 by 43 weeks; all 6 noted breast tenderness. |
| Büchter and colleagues, European Journal of Endocrinology, 199816 | Review of 42 treated men at one institute | 21 men with hypothalamic disorders (11 idiopathic hypogonadotropic hypogonadism, 10 Kallmann syndrome) given GnRH or hCG/hMG; 21 with hypopituitarism given hCG/hMG | Courses of GnRH or hCG/hMG; dose not stated in the PubMed entry | Totals for all 42 men and all treatments, not GnRH alone: sperm in 54 of 57 courses, pregnancies in 26 of 36 courses started for that purpose; in the 21 hypothalamic cases GnRH and hCG/hMG were not statistically different in duration to sperm or pregnancy rates (arm sizes and allocation not stated in the PubMed entry). |
| Dwyer and colleagues, Journal of Clinical Endocrinology and Metabolism, 201317 | Randomized, open-label | Men with GnRH deficiency, testes under 4 mL, no cryptorchidism and no prior gonadotropin therapy | 24 months of pulsatile GnRH alone, or 4 months of recombinant FSH then 24 months of GnRH | Sperm in the ejaculate in 7 of 7 men after FSH pretreatment and 4 of 6 on GnRH alone; with pulsatile GnRH the groups had similar hormonal responses and significant testicular growth; trends toward higher maximal sperm counts after FSH. |
| Zhang and colleagues, American Journal of Men's Health, 20198 | Open-label, nonrandomized; participants chose their treatment | 28 azoospermic men with congenital hypogonadotropic hypogonadism (CHH), aged 16 to 34 | Pump giving gonadorelin subcutaneously every 90 min (n = 10) or cyclical hCG/hMG (n = 18), up to 24 months | Median time to spermatogenesis 6 vs 14 months (p = .01); spermatogenesis in 90% vs 83.3% (not significantly different, p = .548); testis volume and penile length rose in both groups without a significant difference between them. |
| Zheng and colleagues, Journal of Clinical Endocrinology and Metabolism, 201718 | Prospective, self-controlled, 3 months | 40 men with hypogonadotropic hypogonadism from congenital combined pituitary hormone deficiency | Pulsatile GnRH subcutaneously for 3 months | 24 of 40 (60%) responded, with LH and FSH in the normal range and testosterone 8.67 ± 4.83 nmol/L at 3 months, and 8 of those 24 achieved spermatogenesis; 16 of 40 had a poor response; MRI showed no correlation between response and pituitary height or stalk integrity. |
| Li and colleagues, International Journal of Endocrinology, 201519 | Retrospective; 22 untreated men with hypogonadotropic hypogonadism (HH) and 20 healthy controls, then the men with HH against their own baseline | 22 young men with HH, mean age 21.15 ± 1.96 years | Pump, 10 µg per 90-min pulse, 160 µg a day, for 6 months | Osteoporosis in 45.45% of men with HH vs 10.00% of controls; after 6 months bone density at lumbar spine 2-4, femoral neck and total hip rose (P = 0.002, 0.003, 0.003). |
| Jiang and colleagues, Translational Andrology and Urology, 202520 | Retrospective; values compared with the same men's values before treatment | 54 adult men with CHH; mean follow-up 15.9 months (range 3 to 40) | Pump, initial 10 µg every 90 min (16 pulses in 24 h), adjusted in 5 µg steps | Testicular volume 3.19 ± 1.66 mL before treatment and 6.22 ± 1.85, 8.90 ± 2.36 and 9.73 ± 1.93 mL at 0.5, 1 and 2 years; 34 of 45 men treated over 0.5 year collected semen and 27 produced spermatozoa. |
| Wang and colleagues, Endocrine Connections, 202511 | Retrospective, single centre, before and after | 7 male infants with CHH, aged 6.4 ± 4.4 months at the start | Pump, 5 µg every 90 min subcutaneously, 3 to 5 months | Penile length 1.27 ± 0.71 cm before and 2.43 ± 0.90 after; inhibin B 53.86 ± 11.54 pg/mL before and 218.46 ± 32.34 after (4 infants); testicular volume change not significant (4 infants); testes descended in 6/13 (46.1%) at the end of treatment and re-ascended in 2 infants. |
| Santoro, American Journal of Obstetrics and Gynecology, 19909 | Multicenter trial | 109 women with primary or secondary hypothalamic amenorrhea | Intravenous pulsatile gonadorelin acetate (Lutrepulse); dose not stated in the PubMed entry | Ovulation in 91% of women with primary and 96% with secondary amenorrhea; complications of intravenous line placement 0% to 11% (mean 7%); multiple pregnancy 12%; one case of ovarian hyperstimulation in a woman who also received clomiphene citrate. |
| Sun and colleagues, Chinese Medical Journal, 201510 | Diagnostic accuracy of the gonadorelin stimulation test | 91 people with idiopathic hypogonadotropic hypogonadism, 27 with constitutional delay of growth and puberty, 6 prepubertal children, 20 pubertal adults | Blood samples at 0, 30, 60 and 120 min after GnRH; dose not stated in the PubMed entry | In males, peak LH under 9.74 IU/L gave sensitivity 80.0% and specificity 86.4% for telling hypogonadotropic hypogonadism from constitutional delay of growth and puberty, and basal LH under 0.6 IU/L gave 73.8% and 90.9%, which the authors called moderate; in females, basal LH or FSH cut-offs gave sensitivity 80.0% or 100.0% and specificity 75.0% or 50.0%, and the authors judged the test unnecessary in females. |
The PubMed entries for Hoffman and Crowley, Büchter, Dwyer, Zheng, Santoro, Tranoulis and Sun carry no funding or conflict-of-interest statement, so neither is reported for them.
Deeper analysis: pump versus cyclical gonadotropins in men with CHH (Zhang and colleagues, 2019)
Zhang and colleagues at the Endocrinology Department of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, compared a pulsatile gonadorelin pump with cyclical hCG/hMG in an open-label prospective study that was nonrandomized (American Journal of Men's Health, 2019).8 Participants "were allowed to choose PGP or CGT": 10 chose the pump, which delivered gonadorelin subcutaneously every 90 minutes, and 18 chose cyclical hCG/hMG.8 The primary outcome was the time of qualified spermatogenesis (sperm density ≥0.1 million/ml).8
Spermatogenesis occurred in 9 of 10 men on the pump (90%) and 15 of 18 on cyclical hCG/hMG (83.3%), a difference that was not significant, and the median time to spermatogenesis was 6 months against 14 months (p = .01).8 The authors wrote that the difference in rates "did not provide conclusive evidence that one therapy was better than, or equal to, the other", and gave a power of 0.125 for the noninferiority test, which they attributed to the small number of participants.8 Serum testosterone in the cyclical group "fluctuated more and tended to be higher" than on the pump.8 Listed adverse events were acne (7 cyclical, 2 pump), red induration (0 cyclical, 9 pump) and breast tenderness or gynecomastia development (5 cyclical, 2 pump), with one micro-abscess at a needle site, and the authors wrote that "Overall, the treatments were tolerated well by all subjects in both groups".8
The authors named the nonrandom design "a weakness of this study" and wrote that "The participants self-selected the treatment method because the treatment expenses were paid by the subjects".8 Baseline groups differed in prior treatment (prior hCG or testosterone in 6 of 10 pump users and 2 of 18 in the cyclical group, p = .011), and the authors noted that "The PGP subjects were very motivated, although the pump was inconvenient and the treatment cost was high" and that "The high motivation in this group might have contributed to the favorable PGP results".8 The study was funded by the Guangzhou Science and Technology Project (Industry-University Collaborative Innovation, 201604020090), it was registered as ChiCTR-OPC-16009168, and the authors declared no potential conflicts of interest.8
Deeper analysis: medium- and long-term pump results in adult men with CHH (Jiang and colleagues, 2025)
Jiang and colleagues at the Department of Urology, Affiliated Hospital of Guizhou Medical University, Guiyang, analysed 54 adult men with CHH treated with pulsatile GnRH pumps, comparing testicular volume, penile length, sex hormones and fertility at 6, 12 and 24 months with values before treatment (Translational Andrology and Urology, 2025).20 Of the 28 men not followed for more than 2 years, 19 "were lost to follow-up at various stages".20 The authors name "small sample size, no control group" as limitations, wrote that genetic testing "was not conducted on any patients in this study" because of funding constraints, and wrote that the men "may have had primary pituitary and/or testicular defects".20 The paper lists funding as "None" and states that the authors have no conflicts of interest to declare.20
Two further pump studies and their stated limits
Wang and colleagues treated 7 male infants with CHH at the Henan Provincial Children's Hospital and wrote that "our study is retrospective in nature", that "the number of patients included in this study is small, and the follow-up period is short", that "it remains unclear whether it offers an advantage over gonadotropin therapy", and that pump therapy "had a limited effect on testicular descent".11 The work was supported by the Zhengzhou Science and Technology Huimin Program (grant 2022KJHM00005), and the authors declared no commercial or financial relationships that could be construed as potential conflicts of interest.11
Li and colleagues at the First Affiliated Hospital of Anhui Medical University listed their limits as the rarity of HH, no bone turnover markers or biopsy "due to budget constraints and the unwillingness of subjects", and no comparison with gonadotropin or testosterone treatment.19 The authors declared that there is no conflict of interests regarding the publication of the paper.19
Doses reported in studies and on labels
| Source | Route and pattern | Dose reported |
|---|---|---|
| Zhang and colleagues, men with CHH, 20198 | Subcutaneous pump, every 90 min | 10 µg per pulse initially; adjusted to 15 µg for one man and 3 µg for one, and raised for two others |
| Li and colleagues, young men with HH, 201519 | Subcutaneous pump, one pulse per 90 min | 10 µg per pulse, 160 µg a day in total, for 6 months |
| Jiang and colleagues, men with CHH, 202520 | Subcutaneous pump, 16 pulses in 24 h | Initial 10 µg per pulse, adjusted in 5 µg steps; the stimulation test used gonadorelin acetate (100 µg) intravenously |
| Wang and colleagues, infants with CHH, 202511 | Subcutaneous pump, every 90 min, 3 to 5 months | 5 µg per pulse; for one infant 7 µg, then 8 µg |
| Cystorelin label, cattle ("Not for use in humans")6 | Intravenous or intramuscular (cystic ovaries); intramuscular (timed insemination) | 100 mcg gonadorelin diacetate tetrahydrate (86 mcg gonadorelin) per cow, for cystic ovaries in dairy cattle or timed insemination in lactating dairy and beef cows |
| Factrel label, cattle ("For use in cattle only")5 | Intramuscular | 100 to 200 mcg gonadorelin per cow in a regimen with dinoprost for timed insemination in lactating dairy cows |
The app lists a typical dose of 50 to 100 mcg a day by subcutaneous injection.
Side effects reported
In the pump studies, skin-site effects were reported: red induration in 9 of 10 men (Zhang and colleagues), skin irritation in 10 of 54 men and discomfort while sweating in 29 of 54 (Jiang and colleagues, who also reported needle breakage in 1 man after strenuous exercise), and a rash in 1 of 7 infants (Wang and colleagues).8,20,11 In Hoffman and Crowley's six men, "All subjects noted spontaneous erections, nocturnal emissions, and breast tenderness", and in Zhang and colleagues' trial breast tenderness or gynecomastia development was reported in 2 of 10 pump users.13,8
Foster and colleagues (McMaster University, American Journal of Obstetrics and Gynecology, 1989) described a woman with severe hypogonadotropic hypogonadism given luteinizing hormone-releasing hormone (Factrel) by infusion pump who developed a reaction at the injection sites, with a positive skin prick test; radioallergosorbent testing was negative for IgE antibodies reactive to the hormone, radioimmunoassay found IgE antibody to it, and treatment was discontinued in this patient.21 In women, Santoro reported intravenous line complications of 0% to 11% (mean 7%) and a 12% incidence of multiple pregnancy, and the systematic review by Tranoulis and colleagues (35 studies, 3 randomized and 32 observational, 1,002 women with hypothalamic amenorrhea) reported that the incidence of ovarian hyperstimulation was "low and of mild severity", that multiple gestation was "low but slightly higher" than in the general population, and that intravenous pulsatile GnRH "is rarely associated with" superficial thrombophlebitis.9,22
Bloodwork and markers
Sources in this part
The app lists LH, FSH and testosterone as markers to monitor. In the pump trial of Zhang and colleagues, blood for LH, FSH and testosterone was drawn 30 minutes after a pulse, and the gonadorelin dose was adjusted to maintain normal levels of the three.8
Regulatory and anti-doping status
Each of the five gonadorelin labels returned by a DailyMed search on 16 November 2026 is for cattle: Factrel (Zoetis, NADA 139-237), Cystorelin (Boehringer Ingelheim Animal Health, NADA 098-379), Gonabreed (Parnell), Fertagyl (Merck) and OvaCyst (Bimeda).5,6 The Factrel label reads "For use in cattle only" and the Cystorelin label "Not for use in humans".5,6 Vasylieva and colleagues write that gonadorelin "was Food and Drug Administration approved but is no longer manufactured".7
The WADA Prohibited List 2026, in effect from 1 January 2026, has an S2.2.1 headed "Testosterone-stimulating peptides in males" that names chorionic gonadotrophin (CG), luteinizing hormone (LH), "gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues" and kisspeptin and its agonist analogues.4 S2 is headed "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)".4
Storage and handling
Sources in this part
The Cystorelin label for cattle states "Store at or below 77°F (25°C)", permits brief excursions to 86°F (30°C) and reads "Use within 6 months of first puncture".6 The Factrel label for cattle states "Store at refrigerator temperature 2° to 8°C (36° to 46°F), with excursions permitted to 25°C (77°F)" and "Use contents within 1 month of first vial puncture".5
What is not known
Sources in this part
A search of PubMed on 16 November 2026 for gonadorelin in the title or summary returned 299 records. The same search combined with "testosterone replacement", TRT, anabolic, "post-cycle", "post cycle" or "exogenous testosterone" returned 1 record, titled "Genetic Profiles and Three-year Follow-up Study of Chinese Males With Congenital Hypogonadotropic Hypogonadism"; the search covered only those six terms in the title or summary, and the record is not summarized here. The men's studies in the table enrolled men with idiopathic or congenital hypogonadotropic hypogonadism or congenital combined pituitary hormone deficiency, and Zhang and colleagues list prior hCG or testosterone treatment among the factors significant for spermatogenesis.8
The pharmacokinetic papers listed above give no 80% subcutaneous bioavailability and no time to peak in minutes.14 The Strong Evidence badge is the app's own grade, not a conclusion of the sources, whose studies include retrospective and nonrandomized designs and small groups.20,8
Frequently asked questions
Sources in this part
- 1Fauconnier et al., 1978
- 2Pimstone et al., 1977
- 3Barron et al., 1982
- 4World Anti-Doping Agency, 2026
- 5Zoetis Inc, 2026
- 6Boehringer Ingelheim Animal Health USA Inc, 2025
- 7Vasylieva et al., 2026
- 8Zhang et al., 2019
- 11Wang et al., 2025
- 12Patel et al., 2024
- 15Chikamori et al., 1981
- 16Büchter D, 1998
- 19Li et al., 2015
- 20Jiang et al., 2025
What is the half-life of gonadorelin?
Is gonadorelin banned by WADA?
WADA's 2026 Prohibited List names GnRH and gonadorelin in S2.2.1, testosterone-stimulating peptides in males, under S2, which is prohibited at all times.4
Is gonadorelin the same as GnRH?
Yes: the Factrel label describes gonadorelin as the gonadotropin releasing hormone (GnRH) produced by the hypothalamus, with an amino acid sequence identical to the endogenous hormone.5
Is gonadorelin approved for use in people?
How does gonadorelin compare with hCG in studies?
In a nonrandomized comparison of 28 men with CHH who chose their own treatment, the gonadorelin pump (n = 10) and cyclical hCG/hMG (n = 18) gave a median time to spermatogenesis of 6 versus 14 months (p = .01) and spermatogenesis rates of 90% versus 83.3% that were not significantly different (p = .548); the authors called the rate comparison inconclusive.8 In Büchter and colleagues' review of 42 men, the 21 men with idiopathic hypogonadotropic hypogonadism or Kallmann syndrome were treated with GnRH or hCG/hMG (arm sizes and allocation not stated), and the two were not statistically different in duration to sperm or pregnancy rates in these small groups.16
What doses of gonadorelin did studies report?
What side effects did gonadorelin pump studies report?
The studies report skin-site effects, with red induration in 9 of 10 men (Zhang and colleagues), skin irritation in 10 of 54 men and discomfort while sweating in 29 of 54 (Jiang and colleagues) and a rash in 1 of 7 infants (Wang and colleagues).8,20,11 Other listed events were needle breakage in 1 man (Jiang and colleagues), acne in 2 of 10 pump users, one micro-abscess at a needle site and breast tenderness or gynecomastia development in 2 of 10 pump users (Zhang and colleagues).20,8
Does continuous GnRH exposure stimulate or reduce gonadotropin output?
A 2024 review of GnRH antagonists states that "Non-pulsatile or continuous GnRH production could result in the pituitary response's desensitization and reduced gonadotropin output".12 Separately, in pump therapy, Zhang and colleagues wrote that "A reduced sensitivity to the pulsatile GnRH was noticed after a period of administration", and cited a report that gonadotropin secretion "could be restored after a transient drug withdrawal or increasing the pulsatile GnRH dose".8
Has gonadorelin been studied alongside testosterone replacement?
A search of PubMed on 16 November 2026 for gonadorelin together with "testosterone replacement", TRT, anabolic, "post-cycle", "post cycle" or "exogenous testosterone" returned 1 record, titled "Genetic Profiles and Three-year Follow-up Study of Chinese Males With Congenital Hypogonadotropic Hypogonadism"; the search covered only those six terms in the title or summary, and the record is not summarized here.
Guides, tools and comparisons
References
- Fauconnier JP, et al. Rate of disappearance in plasma of synthetic LH-RH intravenously injected in man. Gynecol Obstet Invest 1978. PMID 378777
- Pimstone B, et al. Metabolic clearance and plasma half disappearance time of exogenous gonadotropin releasing hormone in normal subjects and in patients with liver disease and chronic renal failure. J Clin Endocrinol Metab 1977. PMID 320223
- Barron JL, et al. Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. J Clin Endocrinol Metab 1982. PMID 6210706
- World Anti-Doping Agency. The Prohibited List 2026, in effect from 1 January 2026. WADA 2026. WADA 2026 list
- Zoetis Inc. FACTREL (gonadorelin hydrochloride) injection for cattle: label, DailyMed version 10 published 29 September 2026. DailyMed Factrel label
- Boehringer Ingelheim Animal Health USA Inc. CYSTORELIN (gonadorelin) injectable solution for cattle: label, DailyMed version dated 7 August 2025. DailyMed Cystorelin label
- Vasylieva V, et al. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev 2026. PMID 42862021
- Zhang L, et al. The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. Am J Mens Health 2019. PMID 30569789
- Santoro N. Efficacy and safety of intravenous pulsatile gonadotropin-releasing hormone: Lutrepulse for injection. Am J Obstet Gynecol 1990. PMID 2122733
- Sun QH, et al. Role of Gonadotropin-releasing Hormone Stimulation Test in Diagnosing Gonadotropin Deficiency in Both Males and Females with Delayed Puberty. Chin Med J (Engl) 2015. PMID 26365959
- Wang X, et al. Efficacy and safety of pulsatile GnRH pump therapy in male infants with congenital hypogonadotropic hypogonadism. Endocr Connect 2025. PMID 40099791
- Patel S, et al. GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy. Pharmaceuticals (Basel) 2024. PMID 39861098
- Hoffman AR, Crowley WF. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med 1982. PMID 6813732
- Handelsman DJ, et al. Pharmacokinetics of gonadotropin-releasing hormone: comparison of subcutaneous and intravenous routes. J Clin Endocrinol Metab 1984. PMID 6384253
- Chikamori K, et al. Distribution volume, metabolic clearance and plasma half disappearance time of exogenous luteinizing hormone releasing hormone in normal women and women with obesity and anorexia nervosa. Acta Endocrinol 1981. PMID 7006293
- Büchter D, et al. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol 1998. PMID 9758439
- Dwyer AA, et al. Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2013. PMID 24037890
- Zheng J, et al. Pulsatile GnRH Therapy May Restore Hypothalamus-Pituitary-Testis Axis Function in Patients With Congenital Combined Pituitary Hormone Deficiency: A Prospective, Self-Controlled Trial. J Clin Endocrinol Metab 2017. PMID 28368486
- Li CX, et al. Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism. Int J Endocrinol 2015. PMID 26417369
- Jiang H, et al. Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism (CHH): a retrospective study. Transl Androl Urol 2025. PMID 40800099
- Foster WG, et al. Immunoglobulin-mediated hypersensitivity in response to long-term treatment with gonadorelin hydrochloride (Factrel) in a female patient. Am J Obstet Gynecol 1989. PMID 2653043
- Tranoulis A, et al. Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review and meta-analysis. Fertil Steril 2018. PMID 29605411